TY - JOUR
T1 - What is new in non-muscle-invasive bladder cancer in 2016
AU - Kamat, Ashish M.
AU - Bağcıoğlu, Murat
AU - Huri, Emre
N1 - Publisher Copyright:
© 2017 by Turkish Association of Urology.
PY - 2017/3
Y1 - 2017/3
N2 - Approximately 75% of bladder cancers are non-muscle-invasive bladder cancer (NMIBC), and 50% of NMIBC patients who are treated with transurethral resection (TUR) have a recurrence of the disease and 5–25% of these patients progressed to muscle-invasive disease after repeated recurrences. NMIBC patients receive various treatments aimed at reducing disease recurrence and progression. Although the recurrence rate of disease remains above target, thus increasing treatment cost, the true rate of recurrence after the primary surgery is controversial. Recurrences can be categorized as either true recurrence due to aggressive tumor biology and implantation of floating cancer cells or false recurrence such as small, flat, or carcinoma in situ lesions overlooked in the primary procedure. Here we discuss new diagnostic methods and treatment options to improve outcomes and reduce recurrence rates in NMIBC.
AB - Approximately 75% of bladder cancers are non-muscle-invasive bladder cancer (NMIBC), and 50% of NMIBC patients who are treated with transurethral resection (TUR) have a recurrence of the disease and 5–25% of these patients progressed to muscle-invasive disease after repeated recurrences. NMIBC patients receive various treatments aimed at reducing disease recurrence and progression. Although the recurrence rate of disease remains above target, thus increasing treatment cost, the true rate of recurrence after the primary surgery is controversial. Recurrences can be categorized as either true recurrence due to aggressive tumor biology and implantation of floating cancer cells or false recurrence such as small, flat, or carcinoma in situ lesions overlooked in the primary procedure. Here we discuss new diagnostic methods and treatment options to improve outcomes and reduce recurrence rates in NMIBC.
KW - Bladder cancer
KW - Diagnostic assessment
KW - Intravesical chemotherapy
KW - Intravesical immunotherapy
KW - Predictive markers
UR - http://www.scopus.com/inward/record.url?scp=85013680473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013680473&partnerID=8YFLogxK
U2 - 10.5152/tud.2017.60376
DO - 10.5152/tud.2017.60376
M3 - Review article
C2 - 28270945
AN - SCOPUS:85013680473
SN - 1300-5804
VL - 43
SP - 9
EP - 13
JO - Turk Uroloji Dergisi
JF - Turk Uroloji Dergisi
IS - 1
ER -